Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease: The role of natalizumab

Expert Opinion on Biological Therapy

Volumn 3, Issue 6, 2003, Pages 995-1000

  Ghosh, Subrata ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

4 integrin; Crohn's disease; MADCAM 1; Natalizumab

Indexed keywords

ALICAFORSEN; ALPHA4 INTEGRIN; ANTIBIOTIC AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MLN 02; MONOCLONAL ANTIBODY; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NATALIZUMAB; PLACEBO; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG TOLERABILITY; ENDOTHELIUM CELL; HUMAN; INTESTINE; LICENSING; LYMPHOCYTE; LYMPHOCYTIC INFILTRATION; NONHUMAN; PHASE 2 CLINICAL TRIAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; SIDE EFFECT; TH1 CELL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; CROHN DISEASE; HUMANS; IMMUNOGLOBULINS; INTEGRIN ALPHA4; MUCOPROTEINS; RECEPTORS, LYMPHOCYTE HOMING;

EID: 0041334132     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/eobt.3.6.995.21264     Document Type: Review

References (11)

1. BINION DG, WEST GA, VOLK EE et al.: Acquired increase in leukocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. Lancet (1998) 352:1742-1746.
2. GORDON FH, HAMILTON MI, DONOGHUE S et al.: A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol. Ther. (2002) 16:699-705.
3. GORDON FH, LAI CWY, HAMILTON MI et al.: A randomised placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn's disease. Gastroenterology (2001) 121:268-274.
4. PODOLSKY DK, LOBB R, KING N et al.: Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J. Clin. Invest. (1993) 92:372-380.
5. 7. Gastroenterology (1996) 111:1373-1380.
6. GHOSH S, GOLDIN E, GORDON F et al.: Natalizumab for active Crohn's disease. N. Engl. J. Med. (2003) 348:24-32.
7. YACYCHYN BR, BOWEN-YACYSHYN MB, JEWELL L et al.: A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology (1998) 114:1133-1142.
8. SCHREIBER S, NIKOLAUS S, MALCHOW H et al.: Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology (2001) 120:1339-1346.
9. 7 antibody in ulcerative colitis (UC). Gastroenterology (2000) 118:A874.
10. http://www.elan.com Elan Corp. homepage
11. http://www.biogen.com Biogen homepage